Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CANbridge closes $98mm Series D round

Executive Summary

CANbridge Pharmaceuticals Inc. (developing treatments for orphan diseases and cancer) raised $98mm through its Series D round. General Atlantic and WuXi AppTec co-led (each with an option to invest another $10M) and were joined by RA Management, Hudson Bay Capital Management, YuanMing Prudence Fund, and Tigermed.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies